ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Roswell Park Celebrates 50th Anniversary of Pivotal Congressional Visit

October 20, 2021

Number Of Uninsured To Increase, Report Finds.

October 12, 2001

ODAC Prefers Three-Hour Taxol Infusion. Says Data Dosage Still Uncertain

October 1, 1993

CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.

March 16, 2007

NCAB Okays Effort To Relax $5 Million Limit On Center Core Grants In Cancer Act Renewal

November 19, 1976

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994